These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 32343165)
1. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. Merli M; Defrancesco I; Visco C; Besson C; Di Rocco A; Arcari A; Sica A; Cencini E; Tisi MC; Frigeni M; Grossi P; Bianchi B; Mora B; Bertù L; Bruno R; Passamonti F; Arcaini L Leuk Lymphoma; 2020 Sep; 61(9):2122-2128. PubMed ID: 32343165 [TBL] [Abstract][Full Text] [Related]
2. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159 [TBL] [Abstract][Full Text] [Related]
3. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma. Occhipinti V; Farina L; Viganò M; Capecchi M; Labanca S; Fanetti I; Corradini P; Rumi M Dig Liver Dis; 2019 May; 51(5):719-723. PubMed ID: 30502232 [TBL] [Abstract][Full Text] [Related]
4. Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi. Arcari A; Tabanelli V; Merli F; Marcheselli L; Merli M; Balzarotti M; Zilioli VR; Fabbri A; Cavallo F; Casaluci GM; Tucci A; Puccini B; Pennese E; Di Rocco A; Zanni M; Flenghi L; Gini G; Sartori R; Chiappella A; Usai SV; Tani M; Marino D; Arcaini L; Vallisa D; Spina M Br J Haematol; 2023 May; 201(4):653-662. PubMed ID: 36733229 [TBL] [Abstract][Full Text] [Related]
5. Antiviral therapies for managing viral hepatitis in lymphoma patients. Merli M; Rattotti S; Gotti M; Arcaini L Expert Opin Pharmacother; 2017 Mar; 18(4):363-376. PubMed ID: 28140702 [TBL] [Abstract][Full Text] [Related]
6. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C; J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157 [TBL] [Abstract][Full Text] [Related]
7. Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. Merli M; Rattotti S; Spina M; Re F; Motta M; Piazza F; Orsucci L; Ferreri AJM; Perbellini O; Dodero A; Vallisa D; Pulsoni A; Santoro A; Sacchi P; Zuccaro V; Chimienti E; Russo F; Visco C; Zignego AL; Marcheselli L; Passamonti F; Luminari S; Paulli M; Bruno R; Arcaini L; J Clin Oncol; 2022 Dec; 40(35):4060-4070. PubMed ID: 35714311 [TBL] [Abstract][Full Text] [Related]
8. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Arcaini L; Besson C; Frigeni M; Fontaine H; Goldaniga M; Casato M; Visentini M; Torres HA; Loustaud-Ratti V; Peveling-Oberhag J; Fabris P; Rossotti R; Zaja F; Rigacci L; Rattotti S; Bruno R; Merli M; Dorival C; Alric L; Jaccard A; Pol S; Carrat F; Ferretti VV; Visco C; Hermine O Blood; 2016 Nov; 128(21):2527-2532. PubMed ID: 27605512 [TBL] [Abstract][Full Text] [Related]
9. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective. Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060 [TBL] [Abstract][Full Text] [Related]
10. [The Current Status and Research Progress of Antiviral Therapy in HCV-Associated Lymphoma --Review]. Sun XH; Wan S; Li ZJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1987-1990. PubMed ID: 34893147 [TBL] [Abstract][Full Text] [Related]
11. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype. Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569 [TBL] [Abstract][Full Text] [Related]
12. [Recurrence of malignant lymphoma immediately after treatment for hepatitis C virus using direct-acting antivirals]. Iwane K; Kayahara T; Takabatake H; Morimoto Y; Iseki A; Mizuno M; Notohara K Nihon Shokakibyo Gakkai Zasshi; 2019; 116(2):177-183. PubMed ID: 30745556 [TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment. Visco C; Finotto S World J Gastroenterol; 2014 Aug; 20(32):11054-61. PubMed ID: 25170194 [TBL] [Abstract][Full Text] [Related]
14. Achieving a high cure rate with direct-acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi-clinic demonstration project. Coyer L; Njoya O; Njouom R; Mossus T; Kowo MP; Essomba F; Boers A; Coutinho R; Ondoa P; Trop Med Int Health; 2020 Sep; 25(9):1098-1109. PubMed ID: 32502290 [TBL] [Abstract][Full Text] [Related]
15. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612 [TBL] [Abstract][Full Text] [Related]
16. Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. Rattotti S; Ferretti VV; Rusconi C; Rossi A; Fogazzi S; Baldini L; Pioltelli P; Balzarotti M; Farina L; Ferreri AJM; Laszlo D; Speziale V; Varettoni M; Sciarra R; Morello L; Tedeschi A; Frigeni M; Defrancesco I; Zerbi C; Flospergher E; Nizzoli ME; Morra E; Arcaini L; Hematol Oncol; 2019 Apr; 37(2):160-167. PubMed ID: 30726562 [TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience. Goel A; Bhargava R; Rai P; Aggarwal R Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients. Hosry J; Miranda RN; Samaniego F; Economides MP; Torres HA Int J Cancer; 2018 Mar; 142(5):940-948. PubMed ID: 29047108 [TBL] [Abstract][Full Text] [Related]